The short answer
Clinical psychedelic studies usually dose a known milligram amount of purified or synthetic psilocybin in a controlled setting with preparation and monitoring. That is a different object than “2 grams of dried mushrooms from a jar,” because dried material varies in alkaloid content. Promising trial results are not FDA approval, not personal medical advice, and not a change to federal legality.
Milligrams in trials vs grams on the street
Johns Hopkins Medicine summaries of major depression research describe supervised psilocybin sessions with supportive psychotherapy and structured follow-up — not informal self-experimentation. Imperial College / related imaging work similarly reports oral psilocybin protocols (including 25 mg arms in comparative trials) with neuroimaging endpoints.
- Johns Hopkins Medicine — 2020 major depression study summary
- Johns Hopkins Medicine — 2022 longer-term follow-up summary
- Nature Medicine — brain network integration after psilocybin therapy (2022)
- Nature Communications — lasting brain changes after first 25 mg dose in naïve adults (2026)
When educational tools translate clinical milligrams into approximate dried-mushroom grams, they must assume an average potency. Real samples deviate. See Potency & lab tests and the Dosage calculator notes.
A practical checklist for study claims
- Population — healthy volunteers, treatment-resistant depression, PTSD, end-of-life anxiety? Results may not transfer.
- Dose and form — synthetic/purified mg vs mushroom material; number of sessions.
- Support package — preparation, sitters/therapists, integration. The drug is not studied in a vacuum.
- Controls — placebo, active comparator, blinding quality. Expectancy effects are a known challenge.
- Follow-up length — days vs months. Early mood lifts can fade; durable claims need durable data.
- Conflicts and sponsorship — read funding and author disclosures on the paper or trial registry.
What research evidence is not
- Not a guarantee of benefit for any individual.
- Not proof that unsupervised use is safe.
- Not legal authorization — U.S. federal Schedule I status still applies outside regulated pathways.
- Not a substitute for clinicians, especially with psychiatric history or interacting medications.